In 2022, according to the WHO, cancer accounted for around 10 million deaths worldwide or nearly one in every six deaths. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections including the Human Papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-fluorescent-in-situ-hybridization-fish-market
Data Bridge Market Research analyzes that the Global Fluorescent in Situ Hybridization (FISH) Market is expected to grow at a CAGR of 8.2% in the forecast period of 2023 to 2030 and is expected to reach USD 1,830.55 million by 2030. The consumables segment is projected to propel the market growth as they are widely used in the FISH technology for the diagnosis of genetic disorders in various regions and more due to the availability of more advanced technologies. Especially, these consumables have a broad range of applications for research and clinical purposes among others.
Key Findings of the Study
Growing Burden of Genetic Disorders as well as Cancer
Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities, such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, have been found to be driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, and Pricing in USD
|
|
Segments Covered
|
By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan, rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, U.A.E, Kuwait, Oman, Qatar, Egypt, rest of Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Thermo Fischer Scientific Inc. (U.S.), Bio-Techne (U.S.), Abbott (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), F. Hoffmann- La Roche Ltd (Switzerland), Abnova Corporation (Taiwan), BioDot (U.S.), Abacm plc. (U.K.), Biocare Medical, LLC (U.S.), Zytomed Systems GmbH (Germany), Genemed Biotechnologies, Inc. (U.S.), Bio SB (U.S.), BioGenex (U.S.), Excilone (France), MetaSystems (Germany), BioCat GmbH (Germany), and Kaneka Eurogentec S.A. (Belgium) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global Fluorescent in Situ Hybridization (FISH) market is segmented based on product type, technology, application, usage, end user, and distribution channel.
- Based on product type, the market is segmented into consumables, instrument, and software.
In 2023, the consumables segment of the product type segment is expected to dominate the market
In 2023, the consumables segment is expected to dominate the market due to the rising burden of cancer and trauma incidences. This segment is expected to reach the highest CAGR of 8.8% in the forecast period of 2023 to 2030.
- Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others. In 2023, the RNA fluorescent in situ hybridization segment is expected to dominate the market with a market share of 45.69% due to the rise in the adoption and demand for FISH techniques
- Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and others. In 2023, the cancer research segment is expected to dominate the market with a market share of 45.71% due to a rise in product and probes approval and increasing early diagnosis of diseases
- Based on usage, the market is segmented into clinical, research, and companion diagnostic. In 2023, the research segment is expected to dominate the market with a market share of 48.32% due to the adoption of new technologies and easy accessibility of products
- Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others. In 2023, the diagnostic laboratories segment is expected to dominate the market with a market share of 42.48% due to a rise in patients with various disorders and rising research activities
- Based on distribution channel, the market is segmented into retail sales, direct tender, online sales, and others. In 2023, the retail sales segment is expected to dominate the market with a market share of 58.08% due to enabling large-scale product sales to increase the efficiency of end-user business growth by alerting and working on the most suitable contract opportunities
Major Players
Data Bridge Market Research recognizes the following companies as the major Fluorescent in Situ Hybridization (FISH) market players in the global Fluorescent in Situ Hybridization (FISH) market that include Thermo Fischer Scientific Inc. (U.S.), Bio-Techne (U.S.), Abbott (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), F. Hoffmann- La Roche Ltd (Switzerland), Abnova Corporation (Taiwan), BioDot (U.S.), Abacm plc. (U.K.), Biocare Medical, LLC (U.S.), Zytomed Systems GmbH (Germany), Genemed Biotechnologies, Inc. (U.S.), Bio SB (U.S.), BioGenex (U.S.), Excilone (France), MetaSystems (Germany), BioCat GmbH (Germany), and Kaneka Eurogentec S.A. (Belgium) among others
Market Development
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a global scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL strengthened its dominant position in the global market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improve their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
- In February 2022, Abcam plc. and Twist Bioscience Corporation announced that in accordance with a licensing agreement the company will employ a secret Twist VHH phage library for Abcam plc.'s antibody discovery, development, and commercialization for diagnostic and research applications. In exchange for license fees and commercial milestone payments, Abcam plc. has the option to propose, license, and market antibody sequences for use in diagnostic and research procedures. The rights to the same sequences are still owned by Twist for therapeutic purposes. This has aided the business in engaging in research activities and producing new antibodies that work better
- In March 2021, Agilent Technologies, Inc. acquired Resolution Biosciences (U.S.), a leader in oncology solutions. This acquisition helped the company in expanding oncology diagnostics by accelerating research, solving complex analytical challenges, and improving patients therapies
Regional Analysis
Geographically, the countries covered in the global Fluorescent in Situ Hybridization (FISH) market report are the U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan, rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global Fluorescent in Situ Hybridization (FISH) market during the forecast period of 2023 to 2030
In 2023, North America is expected to dominate the market owing to the higher level of investments by U.S. manufacturers and the increasing prevalence of oncological diseases and chronic disorders in the U.S. North America will continue to dominate the market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and the launch of new products in this region. Additionally, the increasing number of cases of infectious diseases and rare diseases such as cancer cases and the rising geriatric population are expected to further enhance the market growth rate in this region.
Asia-Pacific is estimated to be the fastest-growing region in the global Fluorescent in Situ Hybridization (FISH) market during the forecast period of 2023 to 2030
Asia-Pacific is expected to grow during the forecast period due to the rapid development of medical facilities in emerging economies in this region. In addition to this, the rising level of healthcare expenditure and increasing per-capita income are expected to propel the market growth in this region.
For more detailed information about the global Fluorescent in Situ Hybridization (FISH) market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-fluorescent-in-situ-hybridization-fish-market
